top-home.jpg

Japan VivaGel® condom launch timing impacted by classification review

Marketing Clearance for VivaGel® condom in New Zealand

Starpharma’s Priostar® Glyphosate Patent Allowed in China

Appendix 4C - Quarterly Cashflow Statement

Starpharma raises $3.5M through SPP following $18M Placement

Sexual Health Drug Delivery Agrochemicals Wider Applications
         
 

Starpharma Holdings Limited is a world leader in the development of dendrimer products for pharmaceutical, life-science and other applications.

Starpharma’s lead products based on VivaGel® (SPL7013, astodrimer sodium) are for the management of bacterial vaginosis (BV), and for prevention of transmission of sexually transmitted infections (STIs), including HIV and genital herpes. 

Starpharma has signed separate licence agreements with Ansell Limited and Okamoto Industries. Inc., to market a value-added, VivaGel® condom.  Ansell manufactures and sells leading condom brands worldwide, including LifeStyles®, ZERO® and SKYN®.  Okamoto is the market leader for condoms sold in Japan, which is the world’s second largest condom market.  

 

 

In the wider pharmaceutical and life science fields, Starpharma has specific programs in dendrimer drug delivery, including drug targeting, drug solubilisation, diagnostics and pharmaceutical excipients.

More broadly, Starpharma is exploring dendrimer opportunities in agrochemicals, cosmetics and materials science with applications as diverse as paints, coatings, adhesives, and water remediation.

 
         

invester-center.jpg

Code Last $+/-
SPL 0.520 0.000

Data provided by asx.com.au. Prices are delayed by at least 20 minutes.

© Starpharma Holdings Limited 2014